Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF) (2010 - 2026)

Rigel Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $597000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 1.16% year-over-year to $597000.0 in Q1 2026; TTM through Mar 2026 was $2.4 million, a 0.99% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, up 8.39% from the prior year.
• Depreciation & Amortization (CF) retreated to $597000.0 in Q1 2026 per RIGL's latest filing, from $601000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $613000.0 in Q2 2024 and bottomed at $237000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $400000.0 (2024), against an average of $439764.7.
• Across the five-year window, Depreciation & Amortization (CF) dropped 29.7% in 2022 and jumped 109.25% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $284000.0 in 2022, then rose by 3.17% to $293000.0 in 2023, then soared by 106.14% to $604000.0 in 2024, then dropped by 0.5% to $601000.0 in 2025, then decreased by 0.67% to $597000.0 in 2026.
• Per Business Quant, the three latest RIGL Depreciation & Amortization (CF) figures stand at $597000.0 (Q1 2026), $601000.0 (Q4 2025), and $603000.0 (Q3 2025).